Business Context and Reporting Period
Company: iRhythm Technologies, Inc. (IRTC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: iRhythm is a digital healthcare company providing ambulatory cardiac monitoring services via its Zio System, a wearable biosensor and cloud-based analytics platform. The company operates as a single reportable segment focused on global ambulatory cardiac monitoring.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue, Net | $192,884 | $147,538 | $538,248 | $427,514 |
| Gross Profit | $137,122 | $101,476 | $379,195 | $292,463 |
| Gross Margin | 71.1% | 68.8% | 70.4% | 68.4% |
| Net Loss | $(5,212) | $(46,182) | $(50,130) | $(111,956) |
| Adjusted EBITDA | $21,559 | $(19,886) | $34,620 | $(27,016) |
| Cash & Cash Equivalents | $255,605 | $419,597 | $255,605 | $519,535 |
| Marketable Securities | $309,608 | $115,956 | $309,608 | $115,956 |
| Total Debt (Convertible Notes) | $648,753 | $646,443 | $648,753 | $646,443 |
Note: Debt figures represent the carrying amount of the 1.50% Senior Convertible Notes due 2029. Principal amount is $661.25 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 31% year-over-year (YoY) in Q3 2025 and 26% for the nine-month period, driven by increased volume of iRhythm Services, particularly the Zio AT product line and growth in large healthcare enterprise accounts.
- Profitability Improvement: Net loss narrowed significantly to $5.2 million in Q3 2025 from $46.2 million in Q3 2024. This improvement was primarily due to revenue growth and a $31.8 million decrease in Acquired In-Process Research and Development (IPR&D) expenses, which were $32.1 million in Q3 2024 related to the BioIntelliSense (BioIS) license acquisition.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased 20% YoY in Q3 2025, driven by higher headcount costs, legal fees, and $3.2 million in intellectual property litigation costs. Research and Development (R&D) expenses increased 34% YoY due to employee-related costs and FDA remediation activities.
- Cash Flow: Net cash provided by operating activities turned positive at $54.7 million for the nine months ended September 30, 2025, compared to a use of $15.8 million in the prior year period. Investing activities used $228.3 million, primarily due to net purchases of marketable securities.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects to continue investing in the business to support growth. The company believes current liquidity is sufficient for at least the next 12 months. No specific numerical guidance for future periods was provided in this text.
- Regulatory & Legal Risks:
- DOJ Investigation: The company is appealing a District Court order to disclose documents to the Department of Justice regarding communications with the FDA. The Ninth Circuit Court of Appeal has stayed the production order pending the appeal.
- Patent Litigation: Active lawsuits filed by Welch Allyn and Bardy Diagnostics (subsidiaries of Baxter International) alleging patent infringement. The company denies these allegations and has filed counterclaims against Bardy Diagnostics.
- Securities Litigation: A putative class action lawsuit remains in discovery; individual defendants were dismissed except for the CEO.
- FDA Compliance: The company continues to address Form 483 observations from 2024 inspections regarding complaint handling and medical device reporting.
- Unusual Items:
- IPR&D Charges: A significant one-time charge of $32.1 million occurred in Q3 2024 for the BioIS license acquisition, distorting year-over-year comparisons. Current period charges are minimal ($0.3 million in Q3 2025).
- Impairment Charges: Recorded $2.5 million in impairment charges during the nine months ended September 30, 2025, related to capitalized internal-use software for the Zio Watch, which the company does not intend to commercially launch.
- Verily Termination: The Development Collaboration Agreement with Verily was mutually terminated in August 2025, eliminating future milestone payment obligations.
Investor Verification Checklist
- Reimbursement Rates: Verify the impact of CMS reimbursement rate updates effective January 1, 2025, specifically the decrease in rates for CPT code 93229 (Mobile Cardiovascular Telemetry) and the stability of rates for 93247 and 93243.
- Contractual Allowances: Review the trend in contractual allowance reserves, which increased in 2025 due to billing disruptions from the Change Healthcare cybersecurity incident and higher payer claims denials.
- Legal Exposure: Monitor the status of the DOJ appeal regarding document production and the outcomes of the patent infringement lawsuits filed by Baxter subsidiaries (Welch Allyn and Bardy Diagnostics).
- Debt Conversion: Assess the potential dilution from the $661.25 million Senior Convertible Notes due 2029, noting the conversion price of approximately $147.22 per share and the existence of capped call transactions to mitigate dilution.
- Supply Chain: Confirm the status of single-source vendor relationships for critical components (adhesive, housings) and any potential disruptions from tariffs or geopolitical conflicts.